GlassScriptPhysician profile
Leona Bowman
NPI 1871909408
$10,321.04
in general payments reported to CMS, 2019-2025
50 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $697 · 2021: $1,359 · 2022: $1,780 · 2023: $1,436 · 2024: $2,061 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,970 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.34 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,589.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,350.82 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,077.64 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Novo Nordisk INC | $1,062.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $651.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $566.64 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $554.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $336.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $323.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $313.39 | 2023-2024 | Auvelity |
| Amgen INC. | $272.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $208.36 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.52 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $152.19 | 2021-2025 | |
| Astellas Pharma US INC | $148.42 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leona Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.